Release Date: December 22, 2025
Expiration Date: December 22, 2026
Activity Overview
The characterization of the RAS oncogenes and mutations that lead to their activation has been one of the seminal discoveries in oncology. However, actively exploiting these proteins as a therapeutic strategy in solid-tumor oncology has been made possible only recently with the incorporation of highly specific inhibitors. More recently, novel RAS-directed strategies have been developed, with the potential to address a much wider range of RAS alterations.
This engaging, fast-paced, and interactive Hot Seat program, held in conjunction with the 43rd Annual Chemotherapy Foundation Symposium (CFS®): Innovative Cancer Therapy for Tomorrow™, brings together expert faculty in the management of lung, gastrointestinal, and gynecological malignancies to discuss the current landscape of agents targeting RAS family members across solid tumors, as well as novel strategies in development with the potential to impact a much broader range of alterations. The expert faculty will address current clinical challenges and opportunities in the treatment of RAS-mutated solid tumors.
This educational activity is an archive of the live virtual symposium held on November 14, 2025.
Target Audience
This educational activity is directed toward physicians, pathologists, advanced practice professionals, nurses, pharmacists, and other health care practitioners interested in KRAS-mutated solid tumors.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Assess the role of KRAS/RAS mutations across solid tumors and biomarker testing implications
- Differentiate efficacy and safety profiles of current and emerging KRAS/RAS-targeted therapies in solid tumors
- Apply clinical trial data on KRAS/RAS-targeted therapies to individualized treatment selection for patients with solid tumors
- Develop appropriate adverse-event mitigation and management approaches for patients with solid tumors receiving KRAS/RAS-targeted therapies
Shubham Pant, MD, MBBS
Professor, Department of Gastrointestinal Medical Oncology
Department of Investigational Cancer Therapeutics
Director of Clinical Research
Associate Director for Early Phase Drug Development
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Alligator Bioscience, Arcus, AskGene Pharma, AstraZeneca, Boehringer Ingelheim, BPGbio, Bristol Myers Squibb, Janssen, Jazz Pharmaceuticals, Merck, Nihon Medi-Physics Co Ltd, Novartis, Pfizer, Revolution Medicines, Theriva Biosciences, US WorldMeds, Zymeworks; Grant/Research Funding: Amal Therapeutics, Arcus, Astellas, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Elicio, Famewave, Immuneering, ImmunoMet, Ipsen, Janssen, Jazz Therapeutics, Lilly, Mirati Therapeutics, NGM Pharmaceuticals, Novartis, Pfizer, Revolution Medicines, Zymeworks; Ownership interests in privately held companies: Telperian
Alison Schram, MD
Associate Attending Physician
Early Drug Development and Gynecologic Medical Oncology Services
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Boehringer Ingelheim, Guardant, Merus, Partner Therapeutics, Revolution Medicine; Grant/Research Funding: AstraZeneca, BeiGene, Boehringer Ingelheim, Kura, Lilly, Merus, Partner Therapeutics, Pfizer, Relay, Revolution Medicine
Helena Yu, MD
Attending
Research Director, Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Amgen, AstraZeneca, Black Diamond, Bristol Myers Squibb, Daiichi, Janssen, Pfizer, Taiho; Grant/Research Funding (to institution): AstraZeneca, Cullinan, Daiichi, Janssen, Kumquat, Pfizer, SystImmune, Taiho
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here